Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Reports First-Quarter 2025 Financial Results Waltham, Mass., May 8, 2025 – Global Partners LP (NYSE: GLP) today reported financial results for the first quarter ended March 31, 2025. CEO Commentary "Global delivered solid first-quarter results, highlighting the strength of our integrated a ...

Core Viewpoint - Vivani Medical, Inc. is advancing its miniature, ultra long-acting drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic implants using its proprietary NanoPortal™ technology [4] - The company’s lead programs include NPM-115 (exenatide implant) and NPM-139 (semaglutide implant), designed for chronic weight management with administration once or twice a year [4] - Vivani is also developing NPM-119, a six-month GLP-1 implant for type 2 diabetes treatment [4] Upcoming Events - CEO Adam Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" at the AAPS workshop on May 14, 2025 [2] - A panel discussion featuring Dr. Mendelsohn will address key hurdles and trends in GLP-1 drug development on the same day [3] Market Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, positioning Vivani's differentiated portfolio as a potential attractive option for patients and healthcare providers [5]

Cencora (COR) is slated to report second-quarter fiscal 2025 results on May 7, before market open. In the last reported quarter, the company delivered an earnings surprise of 6.57%. COR's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 4.94%.(Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) Q2 Estimates The Zacks Consensus Estimate for revenues is pegged at $74.82 billion, up 9.4% from the prior-year quarter's level. The consensus ma ...

Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iB ...

Novo Nordisk A/S NVO announced that CVS Health Inc’s CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.This change will take effect on July 1, 2025. “We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,” said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.In ...

Core Viewpoint - The article discusses the potential for investing in undervalued stocks that are mispriced by the market, particularly focusing on the company HIMS and its stock performance. Group 1: Investment Opportunities - The article suggests that there may be beneficial long positions available in HIMS through stock purchases or call options within the next 72 hours [2]. - It emphasizes the importance of conducting personal research before making investment decisions, highlighting that past performance does not guarantee future results [4]. Group 2: Market Positioning - The article encourages investors to consider joining platforms like Out Fox The Street for insights on positioning in undervalued stocks [1]. - It notes that the opinions expressed are those of the author and may not reflect broader market views, indicating a level of independence in the analysis [4].

For companies that had been undergoing fundamental challenges before the tariff volatility set in, the darkening global macroeconomy has served only to complicate matters further. And while it's understandable that investors want to shy away from risk at times likeWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. ...

Eli Lilly and Company TodayLLYEli Lilly and Company$827.87 +9.85 (+1.20%) 52-Week Range$677.09▼$972.53Dividend Yield0.72%P/E Ratio70.70Price Target$1,017.00Add to WatchlistThe world’s largest pharmaceutical stock, Eli Lilly and Company NYSE: LLY, is back in the green in 2025 as of the Apr. 21 close. Shares were down moderately in 2025 through mid-April. However, huge news came out regarding one of the company’s experimental drugs, causing shares to spike by over 14%. That drug is orforglipron, Eli Lilly’s ...

Core Insights - Ascletis Pharma Inc. announced positive topline results from its Phase Ib study of ASC30, an oral once-daily tablet for obesity treatment, demonstrating significant body weight reductions compared to placebo [3][10] - The study utilized three different weekly titration schemes, with the most effective showing a 6.5% placebo-adjusted mean body weight reduction after four weeks [4][5] Group 1: Study Design and Results - The Phase Ib study was randomized, double-blind, and placebo-controlled, conducted in the U.S. with participants having a BMI of 30-40 kg/m² [3] - Three dosing schemes were tested: - Scheme 1 (mid starting dose, slow titration) resulted in a 4.5% placebo-adjusted weight reduction - Scheme 2 (mid starting dose, normal titration) resulted in a 6.5% placebo-adjusted weight reduction - Scheme 3 (high starting dose, fast titration) resulted in a 5.0% placebo-adjusted weight reduction [4][5] - No serious adverse events were reported across all schemes, indicating a favorable safety profile [6] Group 2: Future Development Plans - Based on the Phase Ib results, the company plans to initiate a 13-week Phase IIa study with a "lower starting dose and slower titration" strategy, expected to begin in Q3 2025 [7] - The study protocol has been submitted to the U.S. FDA following preliminary consultations [7] Group 3: Product Information - ASC30 is a first and only investigational small molecule GLP-1 receptor biased agonist, designed for both oral and subcutaneous administration [8][11] - The compound has patent protection until 2044, highlighting its potential for long-term market exclusivity [11] Group 4: Company Overview - Ascletis Pharma Inc. is an innovative biotech company listed on the Hong Kong Stock Exchange, focusing on metabolic diseases and addressing unmet medical needs globally [12] - The company has multiple clinical-stage drug candidates in its pipeline, emphasizing its commitment to research and development [12]

Core Insights - MetaVia Inc. reported promising results from its Phase 1 clinical trial of DA-1726, indicating a dose-dependent response in body weight reduction, with significant differences in BMI and body weight compared to placebo [1][2][4] - DA-1726 demonstrated a maximum weight loss of -6.3% and a mean weight loss of -4.3% at the 32 mg dose, alongside notable reductions in fasting glucose and waist circumference [3][4] - The drug showed a favorable safety profile, with no significant cardiovascular effects observed, and a slight decrease in heart rate across most treatment groups [4][7] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, particularly obesity [10] - The company is advancing DA-1726, a dual agonist targeting GLP-1 and glucagon receptors, which aims to improve weight loss outcomes compared to existing therapies [9][10] Clinical Trial Details - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving 36 subjects, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726 [6] - The trial's primary endpoint was to evaluate the safety and tolerability of DA-1726, while secondary endpoints included pharmacokinetic assessments and exploratory metabolic parameters [6] Future Directions - MetaVia plans to conduct a Phase 1 Part 3 study to evaluate DA-1726 in patients who discontinued other GLP-1 agonists, aiming to demonstrate improved tolerability and weight loss outcomes [5] - Additional cohorts will be added to determine the maximum tolerated dose of DA-1726, with expectations of enhanced efficacy at higher doses [5]